Last reviewed · How we verify
Lamotrigine tablet
Lamotrigine blocks voltage-gated sodium channels and inhibits glutamate release, reducing neuronal excitability.
Lamotrigine blocks voltage-gated sodium channels and inhibits glutamate release, reducing neuronal excitability. Used for Epilepsy (partial seizures, generalized tonic-clonic seizures, Lennox-Gastaut syndrome), Bipolar disorder maintenance treatment (bipolar depression).
At a glance
| Generic name | Lamotrigine tablet |
|---|---|
| Also known as | Lamitrin, Lamogin, Test Group (Lamnet 100 mg), Reference Group (Lamictal 100 mg), Lamotrigine, Lamictal XR |
| Sponsor | Dhaka Medical College |
| Drug class | Anticonvulsant / Mood stabilizer |
| Target | Voltage-gated sodium channels; glutamate release inhibition |
| Modality | Small molecule |
| Therapeutic area | Neurology / Psychiatry |
| Phase | FDA-approved |
Mechanism of action
Lamotrigine stabilizes neuronal membranes by blocking sodium channels, which prevents repetitive neuronal firing. It also inhibits the release of glutamate, an excitatory neurotransmitter, thereby reducing excessive neuronal activity. These combined effects make it effective as an anticonvulsant and mood stabilizer.
Approved indications
- Epilepsy (partial seizures, generalized tonic-clonic seizures, Lennox-Gastaut syndrome)
- Bipolar disorder maintenance treatment (bipolar depression)
Common side effects
- Rash (including Stevens-Johnson syndrome risk)
- Dizziness
- Ataxia
- Diplopia
- Headache
- Nausea
- Somnolence
Key clinical trials
- Lithium Versus Lamotrigine in Bipolar Disorder, Type II (PHASE4)
- Low vs. Standard Daily Doses of Antiepileptic Drugs in Newly Diagnosed, Previously Untreated Epilepsy(STANDLOW) (PHASE4)
- Lamotrigine 25 mg Chewable Tablets, Fasting (PHASE1)
- Lamotrigine 25 mg Chewable Tablets, Non-Fasting (PHASE1)
- Bioequivalence Study of 200 mg Lamotrigine Tablet Under Non-Fasting Conditions (PHASE1)
- Bioequivalence Study of 200 mg Lamotrigine Tablet Under Fasting Conditions (PHASE1)
- Effect of Adding Lamotrigine to Sodium Valproate in Childhood Epilepsy: Clinicolabratory Study (PHASE4)
- Food Study of Lamotrigine Tablets 25 mg to Lamictal® Tablets 25 mg (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Lamotrigine tablet CI brief — competitive landscape report
- Lamotrigine tablet updates RSS · CI watch RSS
- Dhaka Medical College portfolio CI